Services on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista de Salud Pública
Print version ISSN 0124-0064
Abstract
BUELVAS-JIMENEZ, Neudo; SUAREZ-USECHE, Raibel J. and VIELMA-GUEVARA, José R.. NLRP3 inflammasome: A therapeutic option for kidney disease?. Rev. salud pública [online]. 2017, vol.19, n.1, pp.118-122. ISSN 0124-0064. https://doi.org/10.15446/rsap.v19n1.54415.
Objective
To determine if considering inflammasome NLRP3 as a treatment option for kidney disease is possible.
Methods
Literature review related to NLRP3 inflammasome structure, biological function and relationship with renal disease and others (hypertension, diabetes, gout, atherosclerosis, amyloidosis, Alzheimer's disease); the systematic review was made searching in the databases PubMed and SciELO for the following terms: "The NLRP3 inflammasome therapeutic for kidney disease", "NLRP3 nflammasome in kidney disease" in PubMed, and "Inflammasome" for Scielo.
Results
146 documents were found, althoughonly 34 matched the working hypothesis concerning the NLRP3 inflammasome as a central component of various diseases in humans, with potential therapeutic use. The NLRP3 inflammasome is responsible for the maturation of inflammatory pro-interleukin IL-1 β and IL-18, which can be triggered by aggregated or crystalline materials (particles), and by various microorganisms and toxins derived from these; however, the way how activation mechanisms work is not completely clear.
Conclusions
Research on new therapies that focus on removing or inhibiting inflammasome components, both individually and together, is proposed.
Keywords : Inflammation; inflammasomes; chronic renal diseases; hypertension; interleukins (source: MeHS, NLM).
